

+ + + + + + + + + + + + + + + + + +
+ + + + + + + + + + + + + + + + + +
+ + + + + + + + + + + + + + + + + +

Nevada PEBP

Q3 FY2025

Prepared by Client Analytics

Cynthia Eaton (cynthia.eaton@express-scripts.com)

5/30/2025

**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q3 FY25 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

| CDHP Overall Trend | | % Change |
|---|----------|-----------------|
| Current Period - Plan Cost Net PMPM | | \$77.58 |
| Utilization | \$2.74 | 3.8% |
| Unit Cost | \$3.92 | 5.4% |
| Member Share | (\$1.01) | (1.4%) |
| Total Change in Plan Cost Net PMPM | | \$5.65 |
| Previous Period - Plan Cost Net PMPM | | \$71.93 |

Top moving indications and most notable drug changes within the indications are as follows:

- **HIV:** Previous ranked 4th, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$200k (17.8%) to current \$1.3m.
 - Plan Cost Net PMPM ↑ \$1.24 (24.0%) to current \$6.40.
 - Patient Count ↑ 19 to current count of 119.
 - Adjusted Rxs ↑ 113 to current count of 821.
- **Notable Drug Changes within Indication:**
 - **Biktarvy:**
 - Previous ranked 1st, currently ranked 1st, by Plan Cost Net.
 - Plan Cost Net ↑ \$101k (29.5%) to current \$444k.
 - Plan Cost Net PMPM ↑ \$.57 (36.4%) to current \$2.15.
 - Patient Count ↑ 4 to current count of 20.
 - Adjusted Rxs ↑ 27 to current count of 143.
 - **Descovy:**
 - Previous ranked 2nd, currently ranked 2nd, by Plan Cost Net.
 - Plan Cost Net ↑ \$77k (26.5%) to current \$367k.
 - Plan Cost Net PMPM ↑ \$.44 (33.2%) to current \$1.77.
 - Patient Count ↑ 9 to current count of 39.
 - Adjusted Rxs ↑ 60 to current count of 256.

- **Apretude:**
 - Previous ranked 7th, currently ranked 5th, by Plan Cost Net.
 - Plan Cost Net ↑ \$34k (71.4%) to current \$81k.
 - Plan Cost Net PMPM ↑ \$.17 (80.5%) to current \$.39.
 - Patient Count ↑ 4 to current count of 8.
 - Adjusted Rxs ↑ 17 to current count of 44.

- **Gout:** Previous ranked 71st, currently ranked 10th, by Plan Cost Net.
 - Plan Cost Net ↑ \$354k (8697.6%) to current \$359k.
 - Plan Cost Net PMPM ↑ \$1.71 (9163.9%) to current \$1.73
 - Patient Count ↓ 20 to current count of 309.
 - Adjusted Rxs ↓ 48 to current count of 2,014.

- **Notable Drug Changes within Indication:**
 - **Krystexxa:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$353k.
 - Plan Cost Net PMPM: New, current \$1.71.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 8.

 - **Other drug changes in this indication were not notable.**

- **Blood Cell Deficiency:** Previous ranked 59th, currently ranked 13th, by Plan Cost Net.
 - Plan Cost Net ↑ \$261k (2172.0%) to current \$273k.
 - Plan Cost Net PMPM ↑ \$1.26 (2292.4%) to current \$1.32.
 - Patient Count ↑ 3 to current count of 6.
 - Adjusted Rxs ↑ 1 to current count of 18.

- **Notable Drug Changes within Indication:**
 - **Promacta:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$249k.
 - Plan Cost Net PMPM: New, current \$1.20.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 8.

 - **Doptelet:**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$18k.
 - Plan Cost Net PMPM: New, current \$.09.
 - Patient Count: New, current count of 1.

- Adjusted Rxs: New, current count of 3.
- Other drug changes in this indication were not notable.

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$92.87 compared to CDHP PEBP of \$77.58.
- Peer experienced Trend of 17.8%, compared to CDHP PEBP Trend of 7.9%

EPO Overall Trend Summaries:

| EPO Overall Trend | | % Change |
|--|----------------|-----------------|
| Current Period - Plan Cost Net PMPM | | \$172.96 |
| Utilization | \$8.55 | 5.6% |
| Unit Cost | \$11.38 | 7.4% |
| Member Share | (\$0.28) | (0.2%) |
| Total Change in Plan Cost Net PMPM | \$19.65 | 12.8% |

Previous Period - Plan Cost Net PMPM **\$153.30**

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:** Previous ranked 4th, currently ranked 3rd, by Plan Cost Net.
 - Plan Cost Net ↑ \$250k (37.6%) to current \$915k.
 - Plan Cost Net PMPM ↑ \$6.71 (52.4%) to current \$19.53.
 - Patient Count ↓ 13 to current count of 62.
 - Adjusted Rxs ↓ 63 to current count of 406.
- **Notable Drug Changes within Indication:**
 - **Venclexta:**
 - Previous ranked 4th, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$112k (155.4%) to current \$184k.
 - Plan Cost Net PMPM ↑ \$2.53 (182.8%) to current \$3.92.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↑ 6 to current count of 13.
 - **Lenvima:**
 - New, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net: New, current \$119k.

- Plan Cost Net PMPM: New, current \$2.54.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 5.
- **Koselugo:**
 - Previous ranked 5th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$69k (160.0%) to current \$113k.
 - Plan Cost Net PMPM ↑ \$1.57 (187.9%) to current \$2.41.
 - Patient Count: Remains at 1.
 - Adjusted Rxs ↑ 3 to current count of 5.
- **Seizures:** Previous ranked 6th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$165k (60.9%) to current \$436k.
 - Plan Cost Net PMPM ↑ \$4.08 (78.2%) to current \$9.29.
 - Patient Count ↓ 42 to current count of 208.
 - Adjusted Rxs ↓ 164 to current count of 1,662.
- **Notable Drug Changes within Indication:**
 - **Fintepla:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$166k (99.2%) to current \$333k.
 - Plan Cost Net PMPM ↑ \$3.89 (120.6%) to current \$3.22.
 - Patient Count: Remains at 2.
 - Adjusted Rxs ↑ 8 to current count of 18.
 - **Other drug changes in this indication were not notable.**
- **Gout:** Previous ranked 43rd, currently ranked 14th by Plan Cost Net.
 - Plan Cost Net ↑ \$163k (1299.1%) to current \$175k.
 - Plan Cost Net PMPM ↑ \$3.49 (1449.3%) to current \$3.73.
 - Patient Count: Remains at 118.
 - Adjusted Rxs ↓ 99 to current count of 730.
- **Notable Drug Changes within Indication:**
 - **Krystexxa:**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$167k.
 - Plan Cost Net PMPM: New, current \$3.56.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 4.
 - **Other drug changes in this indication were not notable.**

- **Endocrine Disorders:** Previous ranked 2nd, currently ranked 12th by Plan Cost Net.
 - Plan Cost Net ↓ \$870k (-80.7%) to current \$208k.
 - Plan Cost Net PMPM ↓ \$16.34 (-78.7%) to current \$4.43.
 - Patient Count ↑ 4 to current count of 31.
 - Adjusted Rxs ↑ 10 to current count of 176.
- **Notable Drug Changes within Indication:**
 - **Korlym:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↓ \$926k (-92.0%) to current \$80k.
 - Plan Cost Net PMPM ↓ \$17.67 (-91.2%) to current \$1.71.
 - Patient Count: Remains at 2.
 - Adjusted Rxs ↓ 15 to current count of 2.
 - **Supprelin LA:**
 - New, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net: New, current \$49k.
 - Plan Cost Net PMPM: New, current \$1.04.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 12.
 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO in Plan Cost Net PMPM, however peer has a higher trend.
- Peer experienced Plan Cost Net PMPM of \$127.25 compared to PEBP EPO of \$172.96
- Peer experienced Trend of 22.3%, compared to PEBP EPO of 12.8%

PPO Overall Trend Summaries:

| PPO Overall Trend | | % Change |
|---|---------------|-----------------|
| Current Period - Plan Cost Net PMPM | | \$103.05 |
| Utilization | \$4.44 | 4.7% |
| Unit Cost | \$3.74 | 4.0% |
| Member Share | \$0.85 | 0.9% |
| Total Change in Plan Cost Net PMPM | \$9.03 | 9.6% |
| Previous Period - Plan Cost Net PMPM | | \$94.01 |

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$555k (22.7%) to current \$3m.
 - Plan Cost Net PMPM ↓ \$.07 (-0.5%) to current \$14.36.
 - Patient Count ↑ 82 to current count of 332.
 - Adjusted Rxs ↑ 510 to current count of 2,403.
- **Notable Drug Changes within Indication:**
 - **Rinvoq:**
 - Previous ranked 5th, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$212k (94.5%) to current \$436k.
 - Plan Cost Net PMPM ↑ \$.76 (57.8%) to current \$2.09.
 - Patient Count ↑ 7 to current count of 19.
 - Adjusted Rxs ↑ 52 to current count of 134.
 - **Skyrizi Pen:**
 - Previous ranked 4th, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$105k (46.2%) to current \$333k.
 - Plan Cost Net PMPM ↑ \$.25 (18.6%) to current \$1.59.
 - Patient Count ↑ 2 to current count of 13.
 - Adjusted Rxs ↑ 32 to current count of 108.
 - **Adalimumab-RYVK(CF) Autoinject (Biosimilar Drug)**
 - New, currently ranked 7th by Plan Cost Net.
 - Plan Cost Net: New, current \$139k.
 - Plan Cost Net PMPM: New, current \$.66.
 - Patient Count: New, current count of 26.
 - Adjusted Rxs: New, current count of 140.
- **Diabetes:** Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$863k (43.7%) to current \$2.8m.
 - Plan Cost Net PMPM ↑ \$1.93 (16.6%) to current \$13.57.
 - Patient Count ↑ 463 to current count of 1,875.
 - Adjusted Rxs ↑ 5,612 to current count of 22,851.
- **Notable Drug Changes within Indication:**
 - **Mounjaro:**
 - Previous ranked 2nd, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$516k (118.9%) to current \$951k.
 - Plan Cost Net PMPM ↑ \$1.99 (77.6%) to current \$4.55.
 - Patient Count ↑ 190 to current count of 387.
 - Adjusted Rxs ↑ 1,599 to current count of 2,810.

- **Ozempic:**
 - Previous ranked 1st, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$198k (34.8%) to current \$768k.
 - Plan Cost Net PMPM ↑ \$.31 (9.4%) to current \$3.67.
 - Patient Count ↑ 98 to current count of 385.
 - Adjusted Rxs ↑ 771 to current count of 2,504.
- **Trulicity:**
 - Previous ranked 3rd, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↓ \$90k (-39.7%) to current \$137k.
 - Plan Cost Net PMPM ↓ \$.68 (-51.0%) to current \$.66.
 - Patient Count ↓ 35 to current count of 66.
 - Adjusted Rxs ↓ 269 to current count of 439.
- **Cancer:** Previous ranked 3rd, currently ranked 3rd by Plan Cost Net.
 - Plan Cost Net ↑ \$405k (30.0%) to current \$1.8m.
 - Plan Cost Net PMPM ↑ \$.43 (5.4%) to current \$8.40.
 - Patient Count ↑ 41 to current count of 200.
 - Adjusted Rxs ↑ 275 to current count of 1,238.
- **Notable Drug Changes within Indication:**
 - **Idhifa:**
 - New, currently 2nd ranked by Plan Cost Net.
 - Plan Cost Net: New, current \$220k.
 - Plan Cost Net PMPM: New, current \$1.05.
 - Patient Count: New, current count of 2.
 - Adjusted Rxs: New, current count of 7.
 - **Lynparza:**
 - Previous ranked 18th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$102k (911.5%) to current \$113k.
 - Plan Cost Net PMPM ↑ \$.47 (720.6%) to current \$.54.
 - Patient Count: Remains at 1.
 - Adjusted Rxs ↑ 13 to current count of 15.
 - **Venclexta:**
 - Previous ranked 15th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↑ \$89k (596.7%) to current \$104k.
 - Plan Cost Net PMPM ↑ \$.41 (465.2%) to current \$.50.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↑ 13 to current count of 14.

- **HIV:** Previous ranked 5th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$513k (53.4%) to current \$1.5m.
 - Plan Cost Net PMPM ↑ \$1.39 (24.5%) to current \$7.05.
 - Patient Count ↑ 52 to current count of 130.
 - Adjusted Rxs ↑ 291 to current count of 781.
- **Notable Drug Changes within Indication:**
 - **Biktarvy:**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$144k (35.0%) to current \$557k.
 - Plan Cost Net PMPM ↑ \$.23 (9.5%) to current \$2.66.
 - Patient Count ↑ 8 to current count of 26.
 - Adjusted Rxs ↑ 36 to current count of 159.
 - **Descovy:**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$217k (122.6%) to current \$394k.
 - Plan Cost Net PMPM ↑ \$.84 (80.6%) to current \$1.89.
 - Patient Count ↑ 29 to current count of 49.
 - Adjusted Rxs ↑ 138 to current count of 249.
 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$127.25 compared to PEBP PPO of \$103.05
- Peer experienced Trend of 22.3%, compared to PEBP EPO of 9.6%

| Total Overall Trend | | % Change |
|--------------------------------------|--------|-------------|
| Current Period - Plan Cost Net PMPM | | \$98.75 |
| Utilization | \$3.27 | 3.6% |
| Unit Cost | \$4.98 | 5.5% |
| Member Share | \$0.42 | 0.5% |
| Total Change in Plan Cost Net PMPM | | \$8.68 9.6% |
| Previous Period - Plan Cost Net PMPM | | \$90.08 |

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 21.3% in Specialty patients. This resulted in an 18.2% increase in Specialty Days of Therapy.

Trend was mitigated by increased rebates of 16.3%. This produced a negative Unit Cost Trend of (-6.4%) on Specialty drugs and reduced NonSpecialty Unit Cost Trend to 9.7%, combined is 5.5%.

Member Cost contributed to Trend on both Specialty and NonSpecialty drugs. This is due to increased Utilization on Specialty drugs and Drug Mix on NonSpecialty drugs. Primary driven by utilization of more expensive brand drugs.

Key Statistics:

| Nevada PEBP Total | | | |
|-------------------------------------|--------------|--------------|--------|
| Description | Q3 FY25 | Q3 FY24 | Change |
| Average Members per Month | 51,421 | 48,814 | 5.3% |
| Number of Unique patients | 36,713 | 35,002 | 4.9% |
| Members Utilizing the Benefit | 71.4% | 71.7% | -0.3 |
| Gross Cost/Adjusted Rx | \$148.89 | \$140.50 | 6.0% |
| Plan Spend | \$73,998,874 | \$63,900,184 | 15.8% |
| Rebates (estimated) | \$28,297,287 | \$24,327,855 | 16.3% |
| Plan Cost Net | \$45,701,587 | \$39,572,328 | 15.5% |
| Plan Cost Net PMPM | \$159.90 | \$145.45 | 9.9% |
| Non-Specialty Plan Cost Net PMPM | \$79.14 | \$68.97 | 14.8% |
| Specialty Plan Cost Net PMPM | \$80.75 | \$76.48 | 5.6% |
| Generic Fill Rate | 86.7% | 86.4% | 0.3 |
| 90 Day Utilization | 59.5% | 60.4% | -0.9 |
| Retail - Maintenance 90 Utilization | 29.9% | 28.4% | 1.5 |
| Home Delivery Utilization | 29.7% | 32.0% | -2.3 |
| Member Cost Net % | 17.9% | 18.2% | -0.3 |

END OF REPORT